Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration

R Prince Davis, Amy C Schefler, Timothy G MurrayBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, USAPurpose: To report the outcomes of same-day, bilateral intravitreal anti-vascular endothelial growth factor (VEGF) therapy for a cons...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	R Prince Davis, Amy C Schefler, Timothy G Murray
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/eac41589b1624535b0700a01d797e540
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eac41589b1624535b0700a01d797e540
record_format	dspace
spelling	oai:doaj.org-article:eac41589b1624535b0700a01d797e5402021-12-02T03:07:30ZConcomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration1177-54671177-5483https://doaj.org/article/eac41589b1624535b0700a01d797e5402010-06-01T00:00:00Zhttp://www.dovepress.com/concomitant-bilateral-intravitreal-anti-vegf-injections-for-the-treatm-a4693https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483R Prince Davis, Amy C Schefler, Timothy G MurrayBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, USAPurpose: To report the outcomes of same-day, bilateral intravitreal anti-vascular endothelial growth factor (VEGF) therapy for a consecutive series of patients treated for exudative age-related macular degeneration (ARMD).Methods: A consecutive series of 254 eyes of 127 patients received bilateral, same-day anti-VEGF injections of either bevacizumab or ranibizumab between January 1, 2007 and July 1, 2008 and the outcomes were assessed. Approval was obtained from the Institutional Review Board at the University of Miami Miller School of Medicine.Results: Bilateral, same-day anti-VEGF injections were well tolerated in all patients receiving the therapy. Indication for injection was exudative macular degeneration in all patients. The incidence of adverse effects was low, with only four events reported, none of which were serious. Conclusions: In this study, bilateral anti-VEGF injections performed on the same day were preferred over staggered injections and were well tolerated by patients. No major systemic or ocular adverse events were noted, despite the presence of risk factors in a subset of patients. Given that there are serious, albeit rare, complications following anti-VEGF injection, further study with a larger number of patients will be necessary to definitively prove the safety of this treatment modality.Keywords: visual acuity, same-day treatment, bevacizumab, ranibizumab R Prince DavisAmy C ScheflerTimothy G MurrayDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 703-707 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 R Prince Davis Amy C Schefler Timothy G Murray Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
description	R Prince Davis, Amy C Schefler, Timothy G MurrayBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, USAPurpose: To report the outcomes of same-day, bilateral intravitreal anti-vascular endothelial growth factor (VEGF) therapy for a consecutive series of patients treated for exudative age-related macular degeneration (ARMD).Methods: A consecutive series of 254 eyes of 127 patients received bilateral, same-day anti-VEGF injections of either bevacizumab or ranibizumab between January 1, 2007 and July 1, 2008 and the outcomes were assessed. Approval was obtained from the Institutional Review Board at the University of Miami Miller School of Medicine.Results: Bilateral, same-day anti-VEGF injections were well tolerated in all patients receiving the therapy. Indication for injection was exudative macular degeneration in all patients. The incidence of adverse effects was low, with only four events reported, none of which were serious. Conclusions: In this study, bilateral anti-VEGF injections performed on the same day were preferred over staggered injections and were well tolerated by patients. No major systemic or ocular adverse events were noted, despite the presence of risk factors in a subset of patients. Given that there are serious, albeit rare, complications following anti-VEGF injection, further study with a larger number of patients will be necessary to definitively prove the safety of this treatment modality.Keywords: visual acuity, same-day treatment, bevacizumab, ranibizumab
format	article
author	R Prince Davis Amy C Schefler Timothy G Murray
author_facet	R Prince Davis Amy C Schefler Timothy G Murray
author_sort	R Prince Davis
title	Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
title_short	Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
title_full	Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
title_fullStr	Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
title_full_unstemmed	Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
title_sort	concomitant bilateral intravitreal anti-vegf injections for the treatment of exudative age-related macular degeneration
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/eac41589b1624535b0700a01d797e540
work_keys_str_mv	AT rprincedavis concomitantbilateralintravitrealantivegfinjectionsforthetreatmentofexudativeagerelatedmaculardegeneration AT amycschefler concomitantbilateralintravitrealantivegfinjectionsforthetreatmentofexudativeagerelatedmaculardegeneration AT timothygmurray concomitantbilateralintravitrealantivegfinjectionsforthetreatmentofexudativeagerelatedmaculardegeneration
_version_	1718401952594788352

Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration

Ejemplares similares